Elvina Almuradova/LinkedIn
Mar 28, 2025, 13:29
Elvina Almuradova: Second interim analysis confirms the benefit from addition of Pembrolizumab to CRT
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Second interim analysis confirms the benefit from addition of Pembrolizumab to CRT!!!
(Phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 Trial).
Pembrolizumab plus concurrent chemoradiotherapy (CRT), followed by pembrolizumab maintenance resulted;
- 32% reduction** in disease progression risk.
- 40% reduction** in second disease progression (PFS2) risk.
- 33% reduction** in risk of death.
PFS at 3 years 62.7% vs 54.5%.
OS at 3 years 82.6% vs. 74.8%.
Grade ≥3 treatment-related adverse events:
- 69.1% in the pembrolizumab group vs.
- 61.3% in the placebo group.
Immune-mediated adverse events:
- 39% in the pembrolizumab arm vs.
- 17% in the placebo arm (mostly grade 1 or 2).
Treatment-related deaths:
- 2 in each arm.
2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 17:19
Mar 30, 2025, 16:56
Mar 30, 2025, 16:44
Mar 30, 2025, 16:43
Mar 30, 2025, 16:03
Mar 30, 2025, 15:52
Mar 30, 2025, 15:48